文献速递前列腺癌

高强度聚焦超声局灶治疗前列腺癌:前瞻性试验的3年结局

Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial.
PubMed 文献 · BJU Int · 2023-11-14

这项前瞻性研究评估了局灶高强度聚焦超声(HIFU)治疗局限性前列腺癌的3年肿瘤学和功能结局,采用定期消融后饱和穿刺活检。91例患者中,3年无失败生存率(任何GG≥2)为44%(95%CI 34-56%),癌症特异性生存率100%,无转移生存率99%;尿路和肠道功能3个月内恢复基线,17例(21%)报告勃起功能有意义的恶化。

要点

  • 3年无失败生存率(任何GG≥2)为44%(95%CI 34-56%),第二定义下为65%(95%CI 55-77%)。
  • 3年癌症特异性生存率100%,无转移生存率99%,81%患者避免了全腺体治疗。
  • MRI和PSA相对下降(P=0.4)在检测残留疾病方面表现不佳。

核心结论

  • 局灶HIFU治疗局限性前列腺癌显示出优异的功能结局,一半患者在3年后仍无癌。
  • 81%的患者避免了全腺体治疗。
  • 早期随访活检对于及时改变或继续治疗方式至关重要,而MRI和PSA在检测前列腺癌复发方面的作用尚不确定。

研究设计与样本

  • 前瞻性研究,采用定期消融后饱和穿刺活检评估局灶HIFU治疗局限性前列腺癌的肿瘤学和功能结局。
  • 纳入标准:≤2个病灶的GG≤3前列腺癌,PSA≤15 ng/mL,临床T1c-T2,预期寿命≥10年。
  • 共纳入91例患者:6例(7%)为GG1,85例(93%)为GG≥2。
  • 83例(91%)接受了至少一次随访活检;6、12、36个月活检依从率分别为84%、67%、51%。
  • 主要终点为无失败生存率(FFS),定义为方案规定的饱和穿刺活检中无临床显著前列腺癌(csPCa)(野内或野外)、无全腺体或全身挽救治疗、无前列腺癌转移或前列腺癌相关死亡。

主要发现

  • 6、12、36个月FFS(任何GG≥2前列腺癌)分别为79%(95%CI 80-88%)、57%(95%CI 48-69%)、44%(95%CI 34-56%)。
  • 第二定义(任何GG≥3或核心受累≥6 mm)下,6、12、36个月FFS分别为88%(95%CI 81-95%)、70%(95%CI 61-81%)、65%(95%CI 55-77%)。
  • 3年癌症特异性生存率100%,无转移生存率99%。
  • MRI阴性预测值高达89%(95%CI 84-93%),PSA相对下降(P=0.4)在检测残留疾病方面表现不佳。
  • 尿路和肠道评估在3个月内恢复基线问卷评分;17例(21%)患者报告勃起功能有意义的恶化;观察到前列腺癌相关焦虑显著下降。

关键数值与推荐

  • 主要终点FFS定义为方案规定的饱和穿刺活检中无csPCa(野内或野外)、无全腺体或全身挽救治疗、无前列腺癌转移或前列腺癌相关死亡。
  • csPCa采用两种定义:(i)任何GG≥2;(ii)任何GG≥3或核心受累≥6 mm。

临床怎么用

  • 作者认为,早期随访活检对于及时改变或继续治疗方式至关重要。
  • 作者指出,MRI和PSA在检测前列腺癌复发方面的作用尚不确定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the oncological and functional outcomes of focal high-intensity focused ultrasound (HIFU) in treating localised prostate cancer (PCa), a 3-year prospective study was undertaken using periodic post-ablation saturation biopsies. PATIENTS AND METHODS: Men with two or fewer lesions of grade group (GG) ≤3 PCa were eligible for participation. Additional criteria included a prostate-specific antigen (PSA) level of ≤15 ng/mL, clinical T1c-T2, and a life expectancy of ≥10 years. The primary endpoint was failure-free survival (FFS), defined as absence of clinically significant PCa (csPCa) in- or out-of-field on protocol-mandated saturation biopsy, no whole-gland or systemic salvage treatment, PCa metastasis, or PCa-related death. Results are reported using two distinct definitions of csPCa: (i) the presence of any GG ≥2 and (ii) any GG ≥3 or core involvement of ≥6 mm. Secondary endpoints were functional patient-reported outcome measures addressing urinary, sexual, and bowel function. RESULTS: A total of 91 patients were included: six (7%) with GG1 and 85 (93%) with GG ≥2. In all, 83 (91%) underwent at least one follow-up biopsy. Biopsy attendance at 6, 12, and 36 months was 84%, 67%, and 51%, respectively. The FFS at these time points for any GG ≥2 PCa was 79% (95% confidence interval [CI] 80-88%), 57% (95% CI 48-69%) and 44% (95% CI 34-56%), respectively. Using the second definition, FFS were 88% (95% CI 81-95%), 70% (95% CI 61-81%) and 65% (95% CI 55-77%), respectively. The 3-year cancer-specific survival was 100%, and freedom from metastasis was 99%. Magnetic resonance imaging (MRI) (negative predictive value of up to 89%, 95% CI 84-93%) and relative decrease of PSA values (P = 0.4) performed poorly in detecting residual disease. Urinary and bowel assessment returned to baseline questionnaire scores within 3 months. In all, 17 (21%) patients reported meaningful worsening in erectile function. A significant decrease of PCa related anxiety was observed. CONCLUSIONS: Focal HIFU treatment for localised PCa shows excellent functional outcomes with half of the patients remaining cancer-free after 3 years. Whole-gland treatment was avoided in 81%. Early follow-up biopsies are crucial to change or continue the treatment modality at the right time, while the use of MRI and PSA in detecting PCa recurrence is uncertain.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kaufmann B, Raess E, Schmid FA, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial. BJU Int. 2023. PMID: 37897088. doi:10.1111/bju.16213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。